HeartBeam Inc.'s VALID-ECG Study Confirms High Diagnostic Accuracy of Synthesized 12-Lead ECG

HeartBeam Inc. (NASDAQ: BEAT) has announced a milestone in cardiac care technology with its VALID-ECG study results, demonstrating a 93.4% diagnostic agreement between its synthesized 12-lead ECG and standard ECGs for arrhythmia assessment. This pivotal study, involving 198 patients across five U.S. clinical sites, underscores the potential of HeartBeam's compact, patient-friendly device to revolutionize how cardiac conditions are monitored outside traditional medical facilities.

The findings, presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society's annual meeting, validate the accuracy and reliability of HeartBeam's technology. With an FDA submission already filed in January 2025, the company is on the brink of introducing a groundbreaking tool for on-demand arrhythmia monitoring. CEO Robert Eno highlighted the importance of this development, emphasizing its role in enabling accurate cardiac assessments anywhere, thereby enhancing patient care and potentially reducing healthcare costs.

Anticipating FDA clearance, HeartBeam has initiated an Early Access Program to fine-tune clinical workflows and prepare for the U.S. market launch. This move signals a significant advancement in making cardiac care more accessible and efficient, with implications for patients, healthcare providers, and the broader medical technology industry.